Start with the chemistry, then ask the clinical question
NAD is nicotinamide adenine dinucleotide, a coenzyme. NAD+ and NADH are its oxidized and reduced forms. Its structure involves nucleotides, rather than the chain of amino acids that defines a peptide. Appearing in a clinic’s peptide or longevity menu does not change that chemical identity.[1]
The more important practical question is what an offered intervention has been shown to do in people. A substance can be essential to normal biology without an added injection producing a proven wellness benefit. To assess a claim about energy, cognition or aging, look for research measuring that outcome with the actual intervention being sold. The importance of a molecule is the start of a research rationale, not the end of an efficacy argument.
This article focuses on the difference between biological importance, changes in measured metabolites and demonstrated clinical benefit. It does not treat oral precursors, NAD+ infusions and other injection routes as interchangeable. Those are different interventions, and results need to remain attached to the one actually studied.
What the often-cited infusion pilot investigated
Grant and colleagues’ 2019 pilot studied eleven healthy men: eight received an NAD+ infusion and three saline. It measured changes in blood and urine metabolites during a six-hour infusion and subsequent observation. That design addressed metabolic handling; it did not establish improved longevity, durable energy or prevention of disease.[2]
| Question | Relevant measurement | What would be an overreach |
|---|---|---|
| Where does infused NAD+ go? | Blood and urine metabolites over time | Calling a metabolite change a proven wellness benefit. |
| Does a person feel or function better? | A defined clinical or functional outcome | Assuming the biochemical result answers it. |
| Does benefit last? | Repeated follow-up over an appropriate period | Projecting hours of observation into years. |
| Does another product work similarly? | Research on that product and route | Transferring the result from an infusion automatically. |
The pilot is useful because it begins to examine an intervention rather than relying solely on theory. It is limited for the same reason all small exploratory studies are limited: it can answer only a narrow question, with few participants and a short observation period. A reader should preserve that useful contribution without upgrading it into evidence for every benefit a clinic attaches to the molecule.
The study’s comparison group also matters. Three saline recipients do not create a large, definitive efficacy trial. Calling a study “controlled” describes one feature of the design; it does not settle its precision, duration or relevance to a specific advertised outcome. The whole design needs to travel with the headline.
A biochemical change is not a patient benefit by itself
- Biological roleWhy the molecule interests researchers
- Measured exposureWhat changes after an intervention
- Clinical outcomeWhether people benefit in a meaningful way
- Durability and riskWhether benefit persists with acceptable harms
These steps require evidence. A plausible connection is not a measured clinical result.
Consider a general claim that an intervention “supports cellular energy.” That wording may describe a biological process, but it leaves the patient outcome undefined. Does the claim mean less fatigue, better exercise capacity, improved daily functioning or a particular laboratory change? Each answer requires a different measurement. Without that definition, a scientific-sounding phrase can be difficult to test and easy to overinterpret.
A useful clinician conversation asks for the outcome first. If the concern is fatigue, ask how the underlying cause will be assessed and what improvement would count as meaningful. If the goal is longevity, ask what human evidence measures that endpoint rather than accepting a laboratory marker as a substitute. This keeps the conversation anchored to a problem the reader actually wants addressed.
Why precursor studies do not settle an injection claim
NAD+ is often discussed alongside nicotinamide riboside and nicotinamide mononucleotide. Even when related molecules participate in a shared biochemical story, a study of one intervention does not verify every other intervention. Route, preparation, dose context and population are part of what was tested. A citation to an oral precursor trial should be labeled as such, rather than silently presented as proof of an NAD+ injection benefit.
The same principle applies within injected products. An intravenous infusion in a research setting does not directly establish the benefit or safety of a different route administered in another setting. This is a reason to ask for matching evidence, not a claim that every other approach has been disproven. Evidence gaps should be described accurately without turning them into either certainty of benefit or certainty of harm.
Our sermorelin article and ipamorelin article show similar problems with moving from hormone-related observations to broad wellness promises. NAD+ has different chemistry, but the reading discipline is the same: identify the intervention and the endpoint before accepting the conclusion.
Sterile preparation is a separate safety issue
The FDA has warned compounders about ingredients unsuitable for sterile drug preparation. It describes reports after NAD+ injections including severe chills, shaking, vomiting and fatigue, sometimes requiring treatment, and says the reactions are consistent with excessive endotoxins. The notice concerns product preparation and reported reactions; it does not provide a universal event rate for all NAD+ products.[3]
This warning illustrates why “naturally present in the body” is not enough to establish the safety of an injected preparation. The material, manufacturing process and intended route introduce additional questions. A biological explanation cannot answer a contamination question, and a reassuring account from another customer cannot verify a specific preparation.
Compounded drugs do not undergo FDA premarket review for safety, effectiveness and quality. A prescription or a polished clinic setting does not convert a compounded preparation into an approved product.[4]
Ask the clinician to explain the source of the proposed product, why it is being considered and how an adverse reaction would be addressed. The answer should be appropriate to the actual preparation and route. This article does not supply a mixing method or an infusion schedule; neither would resolve the missing clinical evidence.
A better way to assess the offer
Separate three documents in your mind: the scientific paper, the product description and the service agreement. The paper should support the claimed benefit. The product description should identify what you would receive. The agreement should explain the cost, follow-up and cancellation. A strong answer in one area cannot compensate for an unanswered question in another.
Our Gala Health review discusses a platform with a broader wellness menu, and the Strut Health review focuses on product clarity before enrollment. Those service comparisons are not endorsements of NAD+ efficacy. The provider shortlists address practical care priorities rather than rank longevity claims.
Before paying, ask which outcome the clinician expects to improve, which controlled human study supports that expectation and what alternatives fit the underlying concern. If the answer relies mainly on the molecule’s cellular role, recognize that the clinical question remains open. A clear acknowledgment of uncertainty is more informative than a long list of benefits without matching evidence.
Use Evidence Compass to keep the actual study details together. For the wider category distinction, read our peptide guide and weight-loss evidence overview.